Study analysis · The lancet. Gastroenterology & hepatology · 2025
This drug combo healed fatty liver in 66% of patients—but made their blood fats dangerously worse.
Two drugs together fixed liver damage in most people, but made their cholesterol and fats worse, which could hurt their hearts.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study gave different pills to people with a liver condition and saw which group got better. Because they randomly assigned who got which pill, we can be fairly sure the pills caused the changes — but only the combo pill worked well, not the single one.
What’s the bottom line?
Scientists tested two drugs together to see if they could heal fatty liver disease in people with advanced scarring. One drug targets fat production, the other helps remove fat from the liver.
How strong is this study?
This was a well-designed experiment: nobody knew who got which pill, and they compared it to a fake pill. That makes the results more trustworthy. But they didn’t test as many people as they planned, so we can’t be 100% sure the results will work for everyone.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
93 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=255)+14.4/20
- Follow-up+10/10
100 / 100
77 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. The study is a randomized controlled trial with double-blinding and a control group, which allows for causal inference. However, the sample size was only 73% of planned, and the primary endpoint was not met for any ervogastat-alone doses, limiting the strength of causal claims to the combination therapy group.
Major COI
Major conflicts that significantly reduce study credibility
The study was fully funded by Pfizer, a company with a direct interest in the outcome, and the combination therapy being tested (ervogastat plus clesacostat) is under development by the funder, raising significant bias risk.
Funders
Conflict Details
Pfizer: Study fully funded by Pfizer, which is developing ervogastat and clesacostat.
No conflict of interest statement was provided in the text. While no authors are explicitly identified as Pfizer employees, the funder has a clear commercial interest in the drugs being tested, and the lack of transparency regarding funder involvement in study design or analysis increases risk of bias.
Key takeaways
- 01
Only the combo of two drugs worked: 66 out of 100 people improved (vs.
- 02
38 out of 100 on placebo).
- 03
But their blood fats got worse.
- 04
The combo helped heal liver damage in more than half the patients, which is promising — but the bad cholesterol changes might make it risky to use long-term.
Surprising findings
- Ervogastat alone failed at all doses, even though it was designed to target fat production in the liver.DGAT2 inhibitors were expected to work alone based on prior animal and early human data—yet none of the four doses showed any meaningful benefit.
- The combination therapy improved liver health but worsened blood fats—exactly the opposite of what the mechanism predicted.The combo was designed to counteract ACC inhibitor side effects (high triglycerides), yet it still produced an 'undesirable lipid profile.'
Practical takeaways
Don’t assume a new liver drug is safe just because it improves liver markers—watch for hidden heart risks.
This study was small, underpowered, and full-text methodology is unavailable. Results may not apply to the general population.
low confidenceWhy this study matters
Combo Worked—Alone Didn’t
Ervogastat alone, at any dose from 25mg to 300mg, did not significantly improve liver health compared to placebo. But when combined with clesacostat (150mg + 5mg), 66% of patients achieved MASH resolution without fibrosis worsening—nearly double the placebo rate of 38%.
People often think one miracle drug can fix complex diseases—but here, only the combo worked, showing that some conditions need multiple targets to heal.
The Hidden Cost: Bad Blood Fats
While the drug combo improved liver health, it was 'associated with a likely undesirable fasting lipid and apolipoprotein profile'—meaning bad cholesterol and triglycerides rose, raising heart disease risk.
A treatment that fixes your liver might be secretly harming your heart—this flips the script on what 'success' means in medicine.
Half the Planned Patients
The study only enrolled 255 patients—73% of its planned 350—reducing statistical power and making results less reliable than a full trial would suggest.
Big medical breakthroughs often start small—but this one was underpowered, meaning the real effect could be even smaller—or bigger.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested two drugs together to see if they could heal fatty liver disease in people with advanced scarring. One drug targets fat production, the other helps remove fat from the liver.
Research results
Only the combo of two drugs worked: 66 out of 100 people improved (vs. 38 out of 100 on placebo). But their blood fats got worse.
What this means - more context
The combo helped heal liver damage in more than half the patients, which is promising — but the bad cholesterol changes might make it risky to use long-term.
The study evaluated the efficacy and safety of ervogastat (DGAT2 inhibitor) alone and in combination with clesacostat (ACC inhibitor) in adults with biopsy-confirmed MASH and fibrosis stages F2-F3.
Ervogastat alone at all doses (25–300 mg) did not significantly improve the primary endpoint of MASH resolution without fibrosis worsening compared to placebo. However, the combination of ervogastat 150 mg plus clesacostat 5 mg increased the proportion of patients achieving the primary endpoint to 66% (vs. 38% with placebo), with a similar result for the 300 mg plus 10 mg dose. The combination therapy was associated with an undesirable fasting lipid and apolipoprotein profile.
Methods Used
Phase 2, double-blind, double-dummy, randomized trial at 198 sites across 11 countries. 255 patients with biopsy-confirmed MASH and F2-F3 fibrosis were randomly assigned to ervogastat (25, 75, 150, or 300 mg), ervogastat plus clesacostat (150 mg + 5 mg or 300 mg + 10 mg), or placebo, twice daily for 48 weeks. Primary endpoint: MASH resolution without fibrosis worsening, or fibrosis improvement without MASH worsening, assessed at week 48. Analysis used full analysis set with missing biopsies as non-responders.
Main Finding
No dose of ervogastat alone significantly improved the composite primary endpoint compared to placebo. The combination of ervogastat 150 mg plus clesacostat 5 mg increased the proportion of patients achieving the primary endpoint to 66% (difference from placebo: 0.27 [90% CI 0.07 to 0.43]); the 300 mg + 10 mg dose showed a similar result (63%, difference: 0.25 [0.04 to 0.42]). The combination therapy was associated with a likely undesirable fasting lipid and apolipoprotein profile.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Sample size was 73% of planned (255/350), reducing statistical power
- •Adverse lipid profile observed with combination therapy, limiting clinical utility
Surprising Findings
Ervogastat alone failed at all doses, even though it was designed to target fat production in the liver.
DGAT2 inhibitors were expected to work alone based on prior animal and early human data—yet none of the four doses showed any meaningful benefit.
Practical Takeaways
Don’t assume a new liver drug is safe just because it improves liver markers—watch for hidden heart risks.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study gave different pills to people with a liver condition and saw which group got better. Because they randomly assigned who got which pill, we can be fairly sure the pills caused the changes — but only the combo pill worked well, not the single one.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized, double-blind, double-dummy design
- Placebo-controlled with multiple active arms
- Use of computer-generated randomization and stratification by fibrosis stage
Weaknesses
- Sample size was only 73% of planned, reducing power to detect differences
- Primary endpoint not met for any ervogastat-alone dose, limiting conclusions
- Full methodology and inclusion/exclusion criteria not available in abstract
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested two drugs together to see if they could heal fatty liver disease in people with advanced scarring. One drug targets fat production, the other helps remove fat from the liver.
Research results
Only the combo of two drugs worked: 66 out of 100 people improved (vs. 38 out of 100 on placebo). But their blood fats got worse.
What this means - more context
The combo helped heal liver damage in more than half the patients, which is promising — but the bad cholesterol changes might make it risky to use long-term.
The study evaluated the efficacy and safety of ervogastat (DGAT2 inhibitor) alone and in combination with clesacostat (ACC inhibitor) in adults with biopsy-confirmed MASH and fibrosis stages F2-F3.
Ervogastat alone at all doses (25–300 mg) did not significantly improve the primary endpoint of MASH resolution without fibrosis worsening compared to placebo. However, the combination of ervogastat 150 mg plus clesacostat 5 mg increased the proportion of patients achieving the primary endpoint to 66% (vs. 38% with placebo), with a similar result for the 300 mg plus 10 mg dose. The combination therapy was associated with an undesirable fasting lipid and apolipoprotein profile.
Methods Used
Phase 2, double-blind, double-dummy, randomized trial at 198 sites across 11 countries. 255 patients with biopsy-confirmed MASH and F2-F3 fibrosis were randomly assigned to ervogastat (25, 75, 150, or 300 mg), ervogastat plus clesacostat (150 mg + 5 mg or 300 mg + 10 mg), or placebo, twice daily for 48 weeks. Primary endpoint: MASH resolution without fibrosis worsening, or fibrosis improvement without MASH worsening, assessed at week 48. Analysis used full analysis set with missing biopsies as non-responders.
Main Finding
No dose of ervogastat alone significantly improved the composite primary endpoint compared to placebo. The combination of ervogastat 150 mg plus clesacostat 5 mg increased the proportion of patients achieving the primary endpoint to 66% (difference from placebo: 0.27 [90% CI 0.07 to 0.43]); the 300 mg + 10 mg dose showed a similar result (63%, difference: 0.25 [0.04 to 0.42]). The combination therapy was associated with a likely undesirable fasting lipid and apolipoprotein profile.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Sample size was 73% of planned (255/350), reducing statistical power
- •Adverse lipid profile observed with combination therapy, limiting clinical utility
Surprising Findings
Ervogastat alone failed at all doses, even though it was designed to target fat production in the liver.
DGAT2 inhibitors were expected to work alone based on prior animal and early human data—yet none of the four doses showed any meaningful benefit.
Practical Takeaways
Don’t assume a new liver drug is safe just because it improves liver markers—watch for hidden heart risks.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study gave different pills to people with a liver condition and saw which group got better. Because they randomly assigned who got which pill, we can be fairly sure the pills caused the changes — but only the combo pill worked well, not the single one.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized, double-blind, double-dummy design
- Placebo-controlled with multiple active arms
- Use of computer-generated randomization and stratification by fibrosis stage
Weaknesses
- Sample size was only 73% of planned, reducing power to detect differences
- Primary endpoint not met for any ervogastat-alone dose, limiting conclusions
- Full methodology and inclusion/exclusion criteria not available in abstract
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This was a well-designed experiment: nobody knew who got which pill, and they compared it to a fake pill. That makes the results more trustworthy. But they didn’t test as many people as they planned, so we can’t be 100% sure the results will work for everyone.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
93 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=255)+14.4/20
- Follow-up+10/10
100 / 100
77 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. The study is a randomized controlled trial with double-blinding and a control group, which allows for causal inference. However, the sample size was only 73% of planned, and the primary endpoint was not met for any ervogastat-alone doses, limiting the strength of causal claims to the combination therapy group.
Major COI
Major conflicts that significantly reduce study credibility
The study was fully funded by Pfizer, a company with a direct interest in the outcome, and the combination therapy being tested (ervogastat plus clesacostat) is under development by the funder, raising significant bias risk.
Funders
Conflict Details
Pfizer: Study fully funded by Pfizer, which is developing ervogastat and clesacostat.
No conflict of interest statement was provided in the text. While no authors are explicitly identified as Pfizer employees, the funder has a clear commercial interest in the drugs being tested, and the lack of transparency regarding funder involvement in study design or analysis increases risk of bias.